Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications

Liège, Belgium, June 18, 2019 - Imcyse, a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases, today announces that it raised €35M ($39.5M) in a series B financing round and through other channels.